INTRODUCTION {#sec1-1}
============

Multidrug-resistant tuberculosis (MDR-TB) has become a major public health problem worldwide and considered to be an obstacle for effective global TB control.\[[@ref1]\] The management of patients with MDR-TB in India is being undertaken by the Revised National Tuberculosis Programme (RNTCP) under the Programmatic Management of Multidrug-Resistant Tuberculosis (PMDT), formerly known as DOTS-Plus. It is a comprehensive management strategy for MDR-TB patients by providing a standardized treatment regimen based on common drug sensitivity testing (DST) profile of the prevalent MDR-TB strains.\[[@ref2]\] DOTS-Plus has been implemented phase wise in India since 2006, with complete geographical coverage achieved in 2013. Out of 130,000 MDR-TB cases emerging annually in India (22% of global burden), 79,000 were among the notified cases of TB in 2015.\[[@ref3]\] Among 79,000 MDR-TB cases, only 36% were diagnosed with suboptimal treatment success rate of 46%. Nearly 64% of cases remained uncovered leading to amplification of resistance in the community. Therefore, these large number of uncovered MDR-TB patients will have to consult private health sector for treatment. Another issue is that the standardized approach provided by DOTS-Plus programs in resource-limited settings has also confronted significant difficulties in the enrollment, diagnosis, and management of MDR-TB patients.\[[@ref4][@ref5][@ref6][@ref7]\] Retention and adherence to therapy remains a major challenge in the treatment of MDR-TB patients as treatment course is expensive, is consisting of more toxic second-line drugs (SLDs), and is lengthy with frequent follow-up cultures. An innovative method based on the local availability of resources is required in order to be devised to address these unmet needs. A modified approach was introduced in order to support the existing national DOTS-Plus program by overcoming these challenges that are encountered in the management of MDR-TB cases.\[[@ref8][@ref9]\] Therefore, the present study has been conducted to determine the treatment outcome in patients of MDR-TB with an alternative approach known as modified DOTS-Plus strategy at Lucknow, India.

METHODS {#sec1-2}
=======

Study design and setting {#sec2-1}
------------------------

It was a prospective cohort study performed among 132 consecutive patients of pulmonary TB referred from Lucknow and other districts of Uttar Pradesh (UP), India, between June 2009 and February 2010 to the Department of Pulmonary Medicine having an established DOTS center and the Department of Microbiology, King George Medical University, Lucknow, India, which is a WHO-recommended Intermediate Reference Laboratory certified by the RNTCP of India.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

All patients provided informed consent before participating in the study. These patients were cases of pulmonary TB with proven culture positive for *Mycobacterium tuberculosis* and resistant to at least isoniazid (INH) and rifampin (RIF) and having age \>18 years. Patients were excluded from the study if they had (1) non-MDR-TB pattern according to drug susceptibility testing (DST) results, (2) taken SLDs \>1 month before confirmation of diagnosis, (3) pregnancy, (4) age \<18 years, and (5) concurrent major medical or psychiatric illnesses at baseline. These exclusions were according to the RNTCP guidelines prevailing at the time of study.\[[@ref8]\]

Diagnosis {#sec2-3}
---------

Pretreatment investigations included sputum smear for acid-fast bacilli (Ziehl--Neelsen staining), culture for *M. tuberculosis* (conventional method using Löwenstein--Jensen medium) and DST (proportion method), complete hemogram, chest X-ray, renal and liver function tests, and thyroid profile. All patients were routinely tested for human immunodeficiency virus (HIV) infection before the initiation of treatment. The BACTEC method (Becton Dickinson, Sparks, MD, USA) for culture and DST for SLDs were also used whenever possible. DST for SLDs was performed when subsequent cultures after 6 months of treatment remained positive. Care was taken to interpret the culture results cautiously along with clinicoradiological data although our laboratory setup underwent regular surveillance for external quality assurance. The minimum inhibitory concentration of the first-line drugs and SLDs used was as follows: streptomycin 16 μg/ml, INH 0.5 μg/ml, RIF 128 μg/ml, ethambutol 8 μg/ml, pyrazinamide (PZA) 50 μg/ml, kanamycin (KM) 30 μg/ml, and levofloxacin or ofloxacin (OFX) 2 μg/ml.\[[@ref10]\]

Management protocol according to the modified DOTS-Plus strategy {#sec2-4}
----------------------------------------------------------------

A committee consisting of clinicians (6), laboratory technicians (2), domiciliary DOT-providers (3), TB health workers (2), health educator (1), and microbiologists (2) was constituted at Lucknow center. One domiciliary DOT-provider from each DOTS center of 18 districts (Kanpur, Basti, Gorakhpur, Allahabad, Faizabad, and Varanasi divisions) was selected and also included in the committee. Operational guidelines as framed by the modified DOTS-Plus strategy were implemented in this study. Modified DOTS-Plus strategy is essentially DOTS-Plus Protocol of the RNTCP based on the WHO guidelines prevailing at that time with relevant modifications according to the Chennai consensus.\[[@ref8][@ref9][@ref11]\] The protocol of the modified DOTS-Plus strategy is described in [Table 1](#T1){ref-type="table"}. All members of the committee underwent 1 month of training regarding implementation of this strategy. Emphasis was given on training of all domiciliary DOT-providers and TB health workers in order to ensure adherence to treatment as well as to access adverse events (AEs) associated with antitubercular therapy. Sample collection of sputum for smear examination and culture inoculation were done daily on an outpatient department basis (excluding Sundays and other holidays). Prior intimation was given to patients for sputum sample deposition at a specified date in order to avoid inconvenience. Regular supply of consumable and nonconsumable staining and culture material was ensured at our established DOTS center. Regular supply of quality-assured drugs was also ensured in collaboration with the Central Tuberculosis Division Ministry of Health and Family Welfare, Government of India, and Uttar Pradesh State Tuberculosis Association. Care was taken to safeguard standardized quality of health care for patients. A subcommittee comprising two clinicians, one microbiologist, and one laboratory technician was framed and assigned to take care of this issue. This subcommittee continued to follow up patients with the prevailing DOTS-Plus guidelines of the RNTCP, particularly in terms of the frequency of culture monitoring, treatment outcomes, as well as monitoring of any AEs. This supervision was performed in order to detect any discrepancy in management with adopted the modified DOTS-Plus strategy as compared to the standard RNTCP guidelines.

###### 

Characteristic features of the modified Directly Observed Treatment Short-Course-Plus strategy

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Components of the modified DOTS plus strategy   
  ----------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Regimen used                                    Standardized regimen provided under supervision\
                                                  IP with six drugs - KM, OFX or LFX, ETO, CS, PZA, EMB\
                                                  CP with four drugs - OFX, ETO, CS, and EMB\
                                                  Duration: IP for a minimum of 6 months extended up to 9 months in patients in case culture positive at the 4^th^ month of treatment followed by CP for a minimum of 18 months leading to a total duration of 24-27 months of treatment\
                                                  Dosage according to weight band: Patients weighing\<45 kg - KM (500 mg), ETO (500 mg), CS (500 mg), OFX (600 mg) or LFX (500 mg), PZA (1250 mg), and EMB (800 mg) and patients weighing ≥45 kg - KM (750 mg), ETO (750 mg), CS (750 mg), OFX (800 mg) or LFX (750 mg), PZA (1500 mg), and EMB (1200 mg)\
                                                  Drugs provided free of cost to the patients every month\
                                                  Ensuring regular supply of quality-assured drugs in collaboration with the CTD, MOHFW, Government of India, and Uttar Pradesh State TB Association

  Treatment monitoring                            Smear examination: Baseline, every monthly during IP and then quarterly during CP\
                                                  Culture examination: 0, 4, 6, 12, 18, and 24 months of treatment\
                                                  Daily sample collection of sputum for smear examination and culture inoculation on an OPD basis (excluding Sundays and other holidays)\
                                                  Monthly follow-up to the outpatient clinic to complete self-administered treatment\
                                                  Total duration of follow-up at least 2 years after the initiation of treatment\
                                                  Prior intimation or reminder given to patients for sputum sample deposition at a specified date\
                                                  Ensuring regular supply of consumable and nonconsumable staining and culture material

  Surveillance of AEs                             Clinical symptoms and AEs recorded at each visit under the supervision of a clinician\
                                                  AEs recording based primarily on clinical evidence under the supervision of clinician further supported by laboratory investigations\
                                                  AEs considered only when reflected at least by one abnormal laboratory value confirmed by a repeat test\
                                                  AEs considered major, if required change in the regimen, i.e., stoppage of offending drug or substitution with other drug\
                                                  PAS as a substitute drug for any one bactericidal (KM, OFX, ETO, and PZA) or two bacteriostatic drugs (CS and EMB) in case of occurrence of AEs

  Health education and family counseling          Provision of counseling and intense health education to all patients and their family members prior to treatment initiation and during all follow-up visits\
                                                  Counseling about the disease, DOTS-plus treatment, importance of treatment adherence, TB transmission, coughing etiquette, proper disposal of sputum, and use of contraception in order to avoid pregnancy during treatment and nutrition\
                                                  Encouragement to maintain personal hygiene and were asked to keep doors and windows open during day time\
                                                  Provision of opportunities to discuss about emotional needs and problems\
                                                  Counseling to family members to provide love and care to the patient\
                                                  Motivation of patients and their family members not to stop treatment despite all its discomforts as it is the last resort that stands between life and death

  Adherence                                       Checking empty blister packs on every follow-up visits\
                                                  Provision of contact numbers of committee members to patients for reporting any issues including AEs\
                                                  Appointment for consultation by clinician to fix issues at the earliest for ensuring treatment adherence\
                                                  Arrangement of home visits if any patient was reported to be absent for periodic follow-up\
                                                  Provision of medicines at residence by DOT provider if patient is unable to collect from the center

  Treatment outcome                               Cure: At least two of the last three cultures at 12, 18, and 24 months (either all the three or the last two) were negative\
                                                  Failure: At least two of the last three cultures at 12, 18, and 24 months (either all the three or the last two) were positive\
                                                  Death: Patient died for any reason during the course of MDR-TB treatment\
                                                  Still on treatment: When for any reason, was receiving the treatment at the time of preparation of treatment outcome report\
                                                  Lost to follow-up or default: When initiated on prescribed regimen but did not turn up for follow-up during any stage of the study\
                                                  Smear conversion: Two negative consecutive sputum smears after treatment initiation\
                                                  Time to smear conversion: Time interval between the date of MDR-TB treatment initiation and the date of the first of two negative consecutive smears\
                                                  Culture conversion: Two negative consecutive cultures after treatment initiation\
                                                  Time to culture conversion: Time interval between the date of MDR-TB treatment initiation and the date of the first of two negative consecutive cultures

  Data collection                                 Maintaining systematic records of demographic profile including address, contact number, treatment regimen, doses, duration, adverse events, investigation results, and treatment outcome for all patients initiated on second-line treatment\
                                                  Recording of data recorded in a predesigned proforma
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TB: Tuberculosis, IP: Intensive phase, KM: Kanamycin, OFX: Ofloxacin, LFX: Levofloxacin, ETO: Ethionamide, CS: Cycloserine, PZA: Pyrazinamide, EMB: Ethambutol, CP: Continuation phase, CTD: Central TB division, MOHFW: Ministry of Health and Family Welfare, OPD: Outpatient department, PAS: Para-amino salicylic acid, DOT: Directly observed treatment, DOTS: DOT short-course, MDR-TB: Multidrug-resistant tuberculosis, CP: Continuation phase, AEs: Adverse events

Data analysis {#sec2-5}
-------------

Data were single entered on Microsoft Excel 2007 sheet, and the accuracy of the entry was verified against the original paper forms. The data were further checked for any errors and then analyzed using descriptive statistics. Absolute and relative frequency counts and measures of central tendency (mean) were calculated. Measure of dispersion such as standard deviation was also calculated. Chi-square test, Fisher\'s exact test, Student\'s *t*-test, and Mann--Whitney *U*-test were used for univariate analyses. Cumulative survival was compared by using the Kaplan--Meier method with the log-rank test. *P* \< 0.05 was considered statistically significant. All statistical analyses were performed using Epi Info software version 3.5.3 (Centre for Disease Control and Prevention; Atlanta; Georgia; USA).

Ethical clearance {#sec2-6}
-----------------

The ethical committee of King George Medical University approved the present study.

RESULTS {#sec1-3}
=======

Out of 132 patients, a total of 98 patients proved to be cases of MDR-TB by culture were enrolled for treatment. All the patients were categorized under re-treatment cases. Thirty-four patients were excluded from the study (non-MDR susceptibility -- 13, \>1 month treatment of SLDs before diagnosis -- 8, migrated/not traced --3, unwillingness for treatment -- 2, major medical/psychiatric illnesses at baseline -- 6, and expiry before the initiation of treatment -- 2). All patients were HIV seronegative after testing. Of them, 68 (69.4%) were males and 30 (30.6%) were females. The mean age and weight were 29.3 ± 9.3 years and 42.9 ± 9.1 kg, respectively. The clinical and demographic profile of the patients is illustrated in [Table 2](#T2){ref-type="table"}. Fifty-six of 98 (57.2%) patients were from areas in and around Lucknow, whereas 42/98 (42.8%) cases were referred from other districts as the DOTS-Plus program was not implemented in UP. The mean duration of total illness was 4.8 ± 3.6 years. Radiologically, 5 (5.1%) patients had unilateral disease, whereas 93 (94.9%) had bilateral disease. The average duration of anti-TB treatment received by the cohort as a whole prior to referral was 26 ± 12.3 months. The cohort was resistant to a mean of 3.17 ± 1.06 drugs. The intensive phase (IP) was extended to 9 months in 30 (30.6%) patients with proven culture positivity at the 4^th^ month. Mean smear and culture conversion time were 3.4 ± 2.1 months (1--11) and 4.6 ± 2.5 months (4--12), respectively. Sputum smear and culture conversion rates were 75/81 (92.5%) and 71/81 (87.7%), respectively, with only ten (10.2%) patients remained culture positive as shown in [Table 3](#T3){ref-type="table"}. Seven patients were resistant to SLDs during the course of treatment among which four were either resistant to KM or OFX in addition to MDR-TB, while the remaining three met the revised WHO diagnosis of extensively drug-resistant (XDR)-TB. These patients were treated either with individualized or standardized regimens for XDR-TB (CAT V under the RNTCP). The clinical characteristics of patients showing unfavorable outcome after treatment with MDR-TB therapy are described in [online Supplementary Table S1](#T4){ref-type="table"}. A wide range of AEs was observed during the treatment, some requiring discontinuation of the offending drug as shown in Tables [4](#T5){ref-type="table"} and [5](#T6){ref-type="table"}. Seventeen (17.4%) patients had major AE requiring drug substitution or permanent discontinuation of drugs. Seven (7.1%) patients required admission to hospital for the occurrence of AE. None of the patients had to discontinue their complete regimen permanently due to major AE. The offending drugs responsible for these major AE were injectable KM (deafness/renal failure), CS (psychosis), ETO (gastrointestinal tolerance), and PZA (arthralgia/hepatitis). No mortality occurred due to major AE in our cohort. Sixteen of thirty (53.3%) female patients were of childbearing age. None of these female patients included in the study conceived during treatment as they were counseled either to avoid intercourse or to use contraception (barrier methods -- 8, intrauterine device -- 3). Of the total 98 patients included in this study, 81 (82.7%) completed the treatment, with 71 (74.5%) declared successfully cured and 10 (10.2%) failed, whereas 7 (7.1%) defaulted and 10 (10.2%) died at the completion of treatment. The reason behind default in all cases was migration due to social reasons. The causes for mortality among the ten patients were found to be acute respiratory failure due to extensive disease (4), accidental trauma (2), viral hemorrhagic fever with multiorgan failure (2), acute coronary syndrome (1), and complicated malaria (1). No significant discrepancy was observed in treatment outcome with reduced frequency of monitoring with culture under modified strategy as reported by the subcommittee in [online Supplementary Table S2](#T7){ref-type="table"}. [Figure 1](#F1){ref-type="fig"} shows Kaplan--Meier plot of the probability of survival among MDR-TB patients from the time of diagnosis. Overall median survival of 98 MDR-TB patients was 26.5 months (95% confidence interval \[CI\]: 25.6--27.4), with 27 months (95% CI: 25.9--28.1) and 26 months (95% CI: 25.2--26.8) for males and females, respectively. No significant difference in survival rate was observed based on gender (*P* = 0.37, log--rank -- Mantel--Cox test). The association of clinical and demographic variables with treatment outcome for MDR-TB patients is described in [Table 6](#T8){ref-type="table"}. Patients were more likely to have poor outcomes if they were drug addicts (odds ratio \[OR\] 0.11; 95% CI: 0.01-0.77; *P* = 0.03), had a previous history of TB episodes \>2 (OR 0.14; 95% CI: 0.11-0.39; *P* \< 0.001), and had resistance to both KM and OFX (OR 0.15; 95% CI: 0.01-0.98; *P* = 0.05). All patients with successful outcome were observed for 1 year after completion of treatment with no relapse.

###### 

Clinical and demographic characteristics of the cohort of 98 patients treated with multidrug-resistant tuberculosis therapy

  Characteristics                                                *n* (%)
  -------------------------------------------------------------- -----------
  Age distribution (years)                                       
   ≤20                                                           13 (13.3)
   21-30                                                         51 (52.1)
   31-40                                                         24 (24.4)
   ≥41                                                           10 (10.2)
  Sex distribution of patients                                   
   Male                                                          68 (69.4)
   Female                                                        30 (30.6)
  Geographical distribution                                      
   Urban                                                         44 (44.9)
   Rural                                                         54 (55.1)
  Weight (kg)                                                    
   ≤30                                                           8 (8.2)
   31-40                                                         33 (33.7)
   41-50                                                         38 (38.8)
   51-60                                                         16 (16.2)
   ≥61                                                           3 (3.1)
  Total duration of illness (years)                              
   \<1                                                           6 (6.1)
   1-2                                                           42 (42.8)
   3-4                                                           38 (38.8)
   \>5                                                           12 (12.3)
  Number of episodes of pulmonary TB for which treatment taken   
   Two                                                           54 (55.1)
   Three                                                         30 (30.6)
   More than three                                               14 (14.3)
   Contact history with TB patients                              20 (20.4)
  Previous TB treatment taken from                               
   Public sector (supervised)                                    14 (14.3)
   Private sector (unsupervised)                                 21 (21.4)
   Public and private both                                       63 (64.3)
  Risk factors                                                   
   Drug addiction                                                5 (5.1)
   Alcoholism                                                    13 (13.3)
   Diabetes mellitus                                             4 (4.1)
  Radiological assessment                                        
   Unilateral                                                    5 (5.1)
   Bilateral                                                     93 (94.9)
   Consolidation                                                 70 (71.4)
   Infiltrate                                                    38 (38.8)
   Cavitation                                                    57 (58.2)
   Fibrotic areas                                                8 (17.1)
   Calcification                                                 2 (2.1)
   Pyo-pneumothorax                                              3 (3.1)
   Effusion                                                      1 (1.1)
  Culture sensitivity pattern                                    
   RIF, INH                                                      36 (36.7)
   RIF, INH, EMB                                                 13 (13.3)
   RIF, INH, EMB, PZA                                            10 (10.2)
   STM, RIF, INH, EMB, PZA                                       12 (12.3)
   STM, RIF, INH                                                 8 (17.1)
   STM, RIF, INH, EMB                                            18 (18.4)
   STM, RIF, INH, PZA                                            1 (1.1)
   Any RIF                                                       98 (100)
   Any INH                                                       98 (100)
   Any EMB                                                       53 (54.1)
   Any PZA                                                       23 (23.5)
   Any STM                                                       39 (39.8)

TB: Tuberculosis, RIF: Rifampin, INH: Isoniazid, EMB: Ethambutol, PZA: Pyrazinamide, STM: Streptomycin

###### 

Bacteriological response of 98 patients treated with multidrug-resistant tuberculosis therapy over 2 years

  Characteristics                   Treatment duration (%)   Nonconverter (%)                                                
  --------------------------------- ------------------------ ------------------ -------------- -------------- -------------- -----------
  Lost to follow-up                 1 (1.1)                  2 (2.1)            4 (4.1)        5 (5.1)        7 (7.1)        
  Expired                           6 (6.1)                  6 (6.1)            7 (7.1)        10 (10.2)      10 (10.2)      
  Patient continuing on treatment   91 (92.8)                90 (91.8)          87 (88.8)      83 (84.7)      81 (82.6)      
  Smear conversion rate                                                                                                      
   Best scenario                    63/91 (69.2)             80/90 (88.9)       81/87 (93.1)   77/83 (92.8)   75/81 (92.5)   6 (6.1)
   Worst scenario                   63/98 (64.3)             80/98 (81.6)       81/98 (82.7)   77/98 (78.6)   75/98 (76.5)   
  Patient still smear positive      28 (28.6)                10 (10.2)          6 (6.1)        6 (6.1)        6 (6.1)        
  Culture conversion rate                                                                                                    
   Best scenario                    61/91 (67.1)             75/90 (83.3)       78/87 (89.7)   74/83 (89.2)   71/81 (87.7)   10 (10.2)
   Worst scenario                   61/98 (62.2)             75/98 (76.5)       78/98 (79.6)   74/98 (75.5)   71/98 (72.4)   
  Patient still culture positive    30 (30.6)                15 (15.3)          9 (9.2)        9 (9.2)        10 (10.2)      

Best scenario: Excluding patients with unfavorable outcome in denominator, Worst scenario: Including patients with unfavorable outcome in denominator

###### 

Clinical characteristics of patients showing unfavorable outcome after treated with multidrug-resistant tuberculosis therapy

  *n*   Sex      Age   Weight   DST pattern               Time in months     Comorbid illness/risk factor if any   Outcome                    
  ----- -------- ----- -------- ------------------------- ------------------ ------------------------------------- --------- ---------------- ---------
  1     Male     45    50       RIF, INH, PZA             Nil                4                                     18        Diabetes         Failure
  2     Male     32    45       RIF, INH                  KM (6)             No                                    No                         Failure
  3     Male     28    31       RIF, INH, EMB             KM (6) OFX (6)     No                                    No                         Failure
  4     Female   38    55       RIF, INH                  Nil                6                                     18        Drug addiction   Failure
  5     Male     51    38       STM, RIF, INH             KM (6)             No                                    No                         Failure
  6     Female   54    45       STM, RIF, INH, EMB, PZA   OFX (6)            4                                     24                         Failure
  7     Female   22    36       STM, RIF, INH, EMB        Nil                4                                     12        Drug addiction   Failure
  8     Female   54    67       RIF, INH, PZA             KM (6) OFX (6)     4                                     6                          Failure
  9     Male     38    50       STM, RIF, INH, EMB, PZA   KM (12) OFX (12)   4                                     12                         Failure
  10    Female   57    39       RIF, INH                  OFX (6)            No                                    No                         Failure
  11    Male     25    45       RIF, INH                  Nil                4                                     24        Drug addiction   Default
  12    Male     30    41       STM, RIF, INH, EMB, PZA   Nil                No                                    No                         Default
  13    Male     46    51       RIF, INH                  Nil                6                                     18        Alcoholism       Default
  14    Female   40    36       STM, RIF, INH             Nil                4                                     12        Drug addiction   Default
  15    Male     20    44       RIF, INH, PZA             Nil                No                                    No        Alcoholism       Default
  16    Female   23    55       RIF, INH, EMB             Nil                4                                     12        Alcoholism       Default
  17    Female   35    42       STM, RIF, INH, PZA        Nil                No                                    No                         Default
  18    Female   21    40       STM, RIF, INH, EMB        Nil                4                                     No                         Expiry
  19    Female   26    46       STM, RIF, INH, EMB, PZA   Nil                4                                     12                         Expiry
  20    Female   20    32       RIF, INH, PZA             Nil                4                                     No                         Expiry
  21    Male     45    42       RIF, INH                  Nil                No                                    No                         Expiry
  22    Male     52    35       RIF, INH, EMB             Nil                No                                    No        Alcoholism       Expiry
  23    Male     61    40       RIF, INH                  Nil                No                                    No                         Expiry
  24    Male     43    48       STM, RIF, INH, EMB, PZA   Nil                No                                    No                         Expiry
  25    Female   25    59       RIF, INH, PZA             Nil                6                                     No                         Expiry
  26    Female   39    44       STM, RIF, INH, EMB, PZA   Nil                No                                    No        Diabetes         Expiry
  27    Female   45    38       STM, RIF, INH, EMB, PZA   Nil                No                                    No                         Expiry

RIF: Rifampin, INH: Isoniazid, EMB: Ethambutol, PZA: Pyrazinamide, STM: Streptomycin, DST: Drug sensitivity testing, KM: Kanamycin

###### 

Frequency of adverse events among 98 patients receiving multidrug-resistant tuberculosis treatment

  Grouped AEs             Specific AEs      Frequency of AEs (%)   Offending drugs
  ----------------------- ----------------- ---------------------- -------------------
  Gastrointestinal        Nausea/vomiting   24 (20.2)              ETO, CS, PZA, OFX
  Anorexia                9 (7.6)           ETO                    
  Gastritis               8 (6.7)           ETO, PAS               
  Hepatitis               3 (2.5)           ETO, PZA               
  Diarrhea                2 (1.7)           ETO, PAS               
  Abdominal pain          1 (0.8)           ETO, PAS               
  Constipation            1 (0.8)           ETO                    
  Ototoxicity             Deafness          12 (10.1)              KM
  Vertigo                 10 (8.4)          KM, CS, OFX            
  Tinnitus                6 (5.1)           KM                     
  Neurological            Dizziness         10 (8.4)               KM, CS, OFX
  Headache                8 (6.7)           CS, KM                 
  Peripheral neuropathy   3 (2.5)           ETO, KM, CS            
  Psychiatric             Psychosis         5 (4.2)                CS
  Depression              1 (0.8)           CS                     
  Others                  Arthralgia        9 (7.6)                PZA
  Visual disturbance      3 (2.5)           EMB, ETO               
  Rash                    2 (1.7)           OFX                    
  Hypothyroidism          1 (0.8)           ETO, PAS               
  Renal failure           1 (0.8)           KM                     
  Overall AEs             119                                      

Sum of column percentages may exceed 100% because a patient may experience more than one adverse event. EMB: Ethambutol, PZA: Pyrazinamide, KM: Kanamycin, CS: Cycloserine, ETO: Ethionamide, OFX: Ofloxacin, PAS: Para-aminosalicylic acid, AEs: Adverse events

###### 

Frequency of major adverse events and suspected agents among the 98 patients receiving multidrug-resistant tuberculosis treatment

  Agents           Specific major AEs observed   Number of patients experiencing major AEs (%)   Number of patients requiring substitution with other drug   Number of patients requiring discontinuation of drugs
  ---------------- ----------------------------- ----------------------------------------------- ----------------------------------------------------------- -------------------------------------------------------
  KM               Deafness                      4 (4.1)                                         1                                                           3
  Tinnitus         1 (1.1)                       1                                               0                                                           
  Renal failure    1 (1.1)                       0                                               1                                                           
  CS               Psychosis                     4 (4.1)                                         0                                                           4
  PZA              Arthralgia                    2 (2.1)                                         1                                                           1
  Hepatitis        2 (2.1)                       1                                               1                                                           
  ETO              Nausea                        1 (1.1)                                         1                                                           0
  Vomiting         1 (1.1)                       1                                               0                                                           
  Hypothyroidism   1 (1.1)                       0                                               1                                                           
  Total            17/98 (17.4)                                                                                                                              

PZA: Pyrazinamide, KM: Kanamycin, CS: Cycloserine, ETO: Ethionamide, AEs: Adverse events

###### 

Bacteriological response of the 98 patients treated with multidrug-resistant tuberculosis therapy over 2 years (expanded version)

  Characteristics                   Treatment duration (months) (%)   Nonconverter (%)                                                                                                                                                                                       
  --------------------------------- --------------------------------- ------------------ -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -----------
  Lost to follow-up                 0 (0.0)                           1 (1.1)            0 (0.0)        0 (0.0)        0 (0.0)        1 (1.1)        1 (1.1)        0 (0.0)        1 (1.1)        0 (0.0)        1 (1.1)        0 (0.0)        2 (2.1)        0 (0.0)        
  Expired                           2 (2.1)                           1 (1.1)            2 (2.1)        1 (1.1)        0 (0.0)        0 (0.0)        0 (0.0)        1 (1.1)        0 (0.0)        0 (0.0)        3 (3.1)        0 (0.0)        0 (0.0)        0 (0.0)        
  Patient continuing on treatment   96 (97.9)                         94 (95.9)          92 (93.8)      91 (92.9)      91 (92.9)      90 (91.8)      89 (90.8)      88 (89.8)      87 (88.8)      87 (88.8)      83 (84.7)      83 (84.7)      81 (82.6)      81 (82.6)      
  Smear conversion rate                                                                                                                                                                                                                                                      
   Best scenario                    1/96 (1.1)                        2/94 (2.1)         28/92 (30.4)   63/91 (69.2)   75/91 (82.4)   80/90 (88.9)   79/89 (88.7)   80/88 (90.9)   79/87 (90.8)   81/87 (93.1)   78/83 (93.9)   77/83 (92.8)   75/81 (92.6)   75/81 (92.6)   6 (6.1)
   Worst scenario                   1/98 (1.1)                        2/98 (2.2)         28/98 (28.6)   63/98 (64.3)   75/98 (76.5)   80/98 (81.6)   79/98 (80.6)   80/98 (81.6)   79/98 (80.6)   81/98 (82.7)   78/98 (79.6)   77/98 (78.6)   75/98 (76.5)   75/98 (76.5)   
  Patient still smear positive      95 (96.9)                         92 (93.8)          64 (65.3)      28 (28.6)      16 (16.3)      10 (10.2)      10 (10.2)      8 (8.2)        8 (8.2)        6 (6.1)        5 (5.1)        6 (6.1)        6 (.1)         6 (6.1)        
  Culture conversion rate                                                                                                                                                                                                                                                    
   Best scenario                    0/96 (0.0)                        1/94 (1.1)         26/92 (28.3)   61/91 (67.1)   73/91 (80.2)   75/90 (83.3)   73/89 (82.1)   76/88 (86.4)   77/87 (88.5)   78/87 (89.7)   75/83 (90.4)   74/83 (89.2)   71/81 (87.7)   71/81 (87.7)   10 (10.2)
   Worst scenario                   0/98 (0.0)                        1/98 (1.1)         26/98 (26.5)   61/98 (62.3)   73/98 (74.5)   75/98 (76.5)   73/98 (74.5)   76/98 (77.6)   77/98 (78.6)   78/98 (79.6)   75/98 (76.5)   74/98 (75.5)   71/98 (72.4)   71/98 (72.4)   
  Patient still culture positive    96 (97.9)                         93 (94.8)          66 (67.3)      30 (30.6)      18 (18.4)      15 (15.3)      16 (16.3)      12 (12.3)      10 (10.2)      9 (9.2)        8 (8.2)        9 (9.2)        10 (10.2)      10 (10.2)      

The analysis performed by the subcommittee has been combined in addition to that of modified DOTS-Plus strategy. DOTS: Directly Observed Treatment Short-Course

![(a) Kaplan--Meier plot of the probability of survival among 98 multidrug-resistant tuberculosis patients from the time of diagnosis. (b) Probability of survival based on gender (*P* = 0.37, log-rank -- Mantel--Cox test)](LI-36-384-g001){#F1}

###### 

Summary of association of clinical and demographic variables with treatment outcome for multidrug-resistant tuberculosis patients

  Characteristics                              Patients with favorable outcome - successfully cured (*n*=71)   Patients with unfavorable outcome - defaulted/expired/failure (*n*=27)   Unadjusted OR (95% CI)   *P*
  -------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------ ---------
  Mean age (years)                             29.17±9.61                                                      29.71±7.74                                                               0.54 (−3.56-4.64)        0.79
  Sex (male), *n* (%)                          54 (76.01)                                                      22 (81.48)                                                               0.72 (0.24-2.20)         0.57
  Mean weight                                  42.62±8.48                                                      40.76±9.65                                                               1.86 (−5.82-2.10)        0.35
  Alcohol abuse, *n* (%)                       9 (12.68)                                                       4 (14.81)                                                                0.83 (0.23-2.98)         0.78
  Drug addiction, *n* (%)                      1 (1.41)                                                        4 (14.81)                                                                0.11 (0.01-0.77)         0.03
  Diabetes mellitus, *n* (%)                   2 (2.82)                                                        2 (7.41)                                                                 0.36 (0.05-2.71)         0.32
  Total duration of illness (years)            4.63±3.52                                                       4.79±3.15                                                                0.16 (−1.38-1.70)        0.84
  Previous number of episodes of TB, *n* (%)                                                                                                                                                                     
   2                                           48 (67.61)                                                      6 (22.22)                                                                1                        
   \>2                                         23 (32.39)                                                      21 (77.78)                                                               0.14 (0.11-0.39)         \<0.001
  Previous contact history with TB, *n* (%)    14 (19.72)                                                      6 (22.22)                                                                0.86 (0.29-2.53)         0.78
  Cavitary lesions on chest X-ray, *n* (%)     42 (59.15)                                                      15 (55.55)                                                               1.16 (0.47-2.83)         0.75
  Resistance to KM, *n* (%)                    0 (0.00)                                                        2 (7.41)                                                                 0.11 (0.01-1.54)         0.09
  Resistance to OFX, *n* (%)                   0 (0.00)                                                        2 (7.41)                                                                 0.11 (0.01-1.54)         0.09
  Resistance to KM and OFX (XDR-TB), *n* (%)   0 (0.00)                                                        3 (11.11)                                                                0.15 (0.01-0.98)         0.05

CI: Confidence interval, TB: Tuberculosis, KM: Kanamycin, OFX: Ofloxacin, XDR: Extensively drug-resistant, OR: Odds ratio

DISCUSSION {#sec1-4}
==========

India constitutes a considerable burden of MDR-TB patients. National programs in developed countries with adequate laboratory facilities may monitor treatment outcome frequently with cultures without constraints. However, in a resource-poor country like India, performing frequent cultures is cumbersome, considering the long waiting period for the results, lack of skilled workforce, and poor quality control of laboratories both in the public and private sectors. A study reported major constraints influencing the outcome such as difficulty in arranging daily DOT for 2 years particularly at peripheral centers, ensuring compliance especially on Sunday and other holidays, lack of access to specialized laboratory facilities, and managing major AEs in field conditions.\[[@ref5]\] Taking note of this huge discrepancy, the Chennai consensus was framed in order to overcome these limitations.\[[@ref9]\] Meanwhile, laboratory services should be strengthened for adequate and timely diagnosis of MDR-TB, and DOTS-Plus should be scaled up as per the target set by the Global Plan to Stop TB 2011--2015.\[[@ref12]\]

The present study has reported successful treatment outcome in 71 (72.5%) and unsuccessful treatment outcomes in 27 (27.5%) patients (failure -- 10 \[10.2%\], treatment default -- 7 \[7.1%\], and death -- 10 \[10.2%\]). Several studies including systematic reviews and meta-analyses revealed variable results, with treatment success rate for MDR-TB patients worldwide ranging from 21% to 83% with considerable unsuccessful treatment outcomes ranging from 29% to 39% (failure or relapse: 6% to 7.6%, treatment default: 12% to 15%, and death: 11% to 13%).\[[@ref3][@ref13][@ref14][@ref15][@ref16][@ref17]\] The treatment outcome remains variable even among different regions of India as shown in [online Supplementary Table S3](#T9){ref-type="table"}. This may be attributed to heterogeneity in the demographic profile of cohorts, frequency of associated comorbid illnesses, settings, methodology, regimens, and definition of outcomes. The success rate was high in our cohort with lower default rate indicating that the modified DOTS-Plus strategy might be effective in improving success outcomes as emphasis was given on patient-centric care, timely management of AE related to SLDs, intense health education, counseling, and psychosocial support apart from reducing follow-up cultures.

###### 

Characteristics of important studies from India showing bacteriological response and outcome of multidrug-resistant tuberculosis

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (study year)                                        Location                            Study period                                                                                    Total number of enrolled MDR-TB cases          Type of regimen used             HIV positive (%)                             Culture sensitivity pattern                                                           Bacteriological response (culture±smear conversion)                               Outcome of treatment for MDR-TB
  ---------------------------------------------------------- ----------------------------------- ----------------------------------------------------------------------------------------------- ---------------------------------------------- -------------------------------- -------------------------------------------- ------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------
  Subhash *et al*., 2003\[[1](#fn1){ref-type="fn"}\]         Vellore, Tamil Nadu                 1997-1999                                                                                       100                                            Individualized                   2/28 (7) (tested for HIV - 28)               RIF+INH - 100%\                                                                       Smear available - 49/55 (89.1%)\                                                  Responders - 26/55 (47.3%)\
                                                                                                                                                                                                                                                                                                                              EMB - 66%\                                                                            Smear conversion - 26/49 (53.1%)\                                                 Failure - 23/55 (41.8%)\
                                                                                                                                                                                                                                                                                                                              STM - 69%\                                                                            Culture available - 26/55 (47.3%)\                                                Defaulted - 45/100 (45%)
                                                                                                                                                                                                                                                                                                                              CS - 11%\                                                                             Culture conversion - 16/26 (61.5%)                                                
                                                                                                                                                                                                                                                                                                                              ETO - 17%\                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                              CFX - 22%                                                                                                                                                               

  Prasad *et al*., 2006\[[2](#fn2){ref-type="fn"}\]          Lucknow, Uttar Pradesh              February 1998-October 2002                                                                      46                                             Individualized                                                                RIF+INH - 8\                                                                          Smear and culture\                                                                Cured - 29 (74.3%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+1 drug - 21\                                                                  Conversion - 29/39 (74.3%)\                                                       Died - 2 (5.1%) yDefaulted - 6 (20.6%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+2 drugs - 17                                                                  Mean - 4.4 months                                                                 Failure - 2 (5.1%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Among cured ones\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Relapse - 2/29 (6.9%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Defaulted - 4/29 (13.8%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Remained smear -ve - 23/29 (79.3%)

  Arora *et al*., 2007\[[3](#fn3){ref-type="fn"}\]           New Delhi                           January 2002-March 2005                                                                         66                                             Standardized                                                                  RIF+INH only - 23 (34.8%)\                                                            53 (80.9%) culture conversion within 9 months\                                    Estimated for 52 patients\
                                                                                                                                                                                                                                                                                                                              RIF+INH+1 drug - 23 (34.8%)\                                                          Among 53 patients\                                                                Cured - 36 (69.2%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+two drugs - 17 (25.8%)\                                                       3 months - 77.4%\                                                                 Defaulted - 6 (11.5%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+three drugs - 3 (4.5%)                                                        6 months - 92.5%                                                                  Died - 6 (11.5%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Treatment failure - 4 (7.7%)

  Dhingra *et al*., 2008\[[4](#fn4){ref-type="fn"}\]         New Delhi                           August 2002-December 2004                                                                       27                                             Individualized                   2                                            RIF+INH - 8\                                                                          Mean smear conversion - 2.3 months\                                               Cured - 13 (48.1%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+1 drug - 9\                                                                   Mean culture conversion - 4.4 months                                              Defaulted - 10 (37.1%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+2 drugs - 5\                                                                                                                                                    Died - 1 (3.7%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH + ≥ 3 drugs - 5                                                                                                                                                 Still on treatment - 1 (3.7%) Referred for surgery - 2 (7.4%)

  Thomas *et al*., 2007\[[5](#fn5){ref-type="fn"}\]          Chennai, Tamil Nadu                 May 1999-December 2003                                                                          66                                             Individualized                                                                RIF+INH - 12 (18%)\                                                                   Smear conversion at 3 months - 23/25 (92%)\                                       Cured - 25 (37.8%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+1 drug - 26\                                                                  Culture conversion 3 months - 16/25 (64%)                                         Failure - 17 (25.7%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+2 drugs - 20\                                                                                                                                                   Defaulted - 16 (24.3%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+3 drugs - 6\                                                                                                                                                    Died - 8 (12.2%)
                                                                                                                                                                                                                                                                                                                              RIF+INH + \> 3 drugs - 2 XDR-TB - 1                                                                                                                                     

  Singla *et al*., 2009\[[6](#fn6){ref-type="fn"}\]          New Delhi                           January 2002-December 2006                                                                      126                                            Standardized                                                                  RIF+INH only - 50 (40%)\                                                              100 (79%) culture conversion within 8 months\                                     Cured - 76 (61%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+1 drug - 41 (33%)\                                                            3 months - 82%\                                                                   Defaulted - 22 (17%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+2 drugs - 25 (20%)\                                                           6 months - 98%                                                                    Died - 24 (19%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+3 drugs - 10 (8%)                                                                                                                                               Treatment failure - 4 (3%)

  Jana *et al*., 2009\[[7](#fn7){ref-type="fn"}\]            West Bengal                         January 2003 -January 2008                                                                      31                                             Individualized                                                                                                                                                                                                                                        Cured - 64.5%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Relapse - 12.9%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Failure - 19.4%

  Datta *et al*., 2009\[[8](#fn8){ref-type="fn"}\]           Srinagar, Jammu and Kashmir         March 2003-February 2007                                                                        52                                             Individualized                                                                RIF+INH only - 7 (13.4%)\                                                             Smear conversion\                                                                 Cured - 37 (77.1%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+1 drug - 16 (30.8%)\                                                          3 months - 30 (57.7%)\                                                            Died - 11 (21.1%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+2 drugs - 16 (30.8%)\                                                         6 months - 44 (84.6%)\                                                            Defaulted - 4 (7.6%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+3 drugs - 5 (9.6%)\                                                           Culture conversion\                                                               Failure - 8 (15.3%) (All XDR-TB)
                                                                                                                                                                                                                                                                                                                              RIF+INH + \> 3 drugs - 8 (15.4%)                                                      3 months - 23 (44.1%)\                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                    6 months - 44 (84.6%)                                                             

  Joseph *et al*., 2011\[[9](#fn9){ref-type="fn"}\]          Tamil Nadu                          Jane 2006-September 2007                                                                        38                                             Standardized                                                                  RIF+INH only - 3\                                                                     Smear\                                                                            Cured - 25 (65.8%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+1 drug - 15\                                                                  3 months - 33 (87%)\                                                              Defaulted - 5 (13.2%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+2 drugs - 15\                                                                 6 months - 33 (87%)\                                                              Died - 3 (7.9%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+3 drugs - 4\                                                                  Culture\                                                                          Treatment failure - 5 (13.2%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+4 drugs - 1 OFX - 5 KM - 1 ETO - 12                                           3 months - 32 (84%)\                                                              XDR-TB among treatment failures- 2/5 (40%)
                                                                                                                                                                                                                                                                                                                                                                                                                    6 months - 33 (87%)\                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                    Culture conversion - 82% in 2 months or less                                      

  Isaakidis *et al*., 2011\[[10](#fn10){ref-type="fn"}\]     Mumbai, Maharashtra                 May 2007-May 2011                                                                               58                                             Individualized or Standardized   100                                          MDR-TB suspect - 13\                                                                  Baseline smear positive - 25\                                                     Cured - 8 (14%) Completed treatment - 5 (9%) Died - 13 (22%) Defaulted - 7 (22%) Failure - 2 (3%) Still on treatment - 23 (40%)
                                                                                                                                                                                                                                                                                                                              Pure MDR (RIF+INH) - 2\                                                               Smear conversion at 4 months - 13/25 (52%)\                                       
                                                                                                                                                                                                                                                                                                                              RIF+INH+other FLD - 15\                                                               Baseline culture positive - 44\                                                   
                                                                                                                                                                                                                                                                                                                              RIF+INH+SLD - 26\                                                                     Culture conversion at 4 months - 23/44 (52%)                                      
                                                                                                                                                                                                                                                                                                                              XDR-TB - 2                                                                                                                                                              

  Nagaraja *et al*., 2012\[[11](#fn11){ref-type="fn"}\]      Bengaluru, Karnataka                January 2005-December 2008                                                                      224                                            Individualized                   5                                            STM+RIF+INH+EMB - 146 (65.2%)\                                                        SRHE - 40.3\                                                                      Cured - 145 (64.7%)\
                                                                                                                                                                                                                                                                                                                              STM+RIF+INH - 39 (17.4%)\                                                             SRH - 48.2\                                                                       Treatment failure - 5 (2.2%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+EMB - 19 (8.5%)\                                                              RHE - 51.3\                                                                       Died - 10 (4.4%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH - 20 (8.9%)                                                                   RH - 55                                                                           Defaulted - 64 (28.5%)

  Kapadia and Tripathi, 2013\[[12](#fn12){ref-type="fn"}\]   Ahmedabad, Gujarat                  August 2007-June 2012                                                                           63                                             Standardized                     2 (3.2)                                      STM+RIF+INH+EMB- 12 (57%)\                                                            Smear conversion at 3 months - 32/48 (66.7%)\                                     Treatment completed - 23\
                                                                                                                                                                                                                                                                                                                              STM+RIF+INH - 4 (19.1%)\                                                              Mean smear conversion - 4.2±2.1 months\                                           Cured - 9/23 (39.2%)\
                                                                                                                                                                                                                                                                                                                              RIF+INH+EMB - 2 (3.2%)\                                                               Culture conversion at 3 months - 27/48 (57.3%)\                                   Still on treatment - 28\
                                                                                                                                                                                                                                                                                                                              RIF+INH - 3 (14.3%)\                                                                  Mean culture conversion - 4.3±2.4 months                                          Failure - 3\
                                                                                                                                                                                                                                                                                                                              Line probe assay\                                                                                                                                                       OFX- 2/XDR-TB - 1\
                                                                                                                                                                                                                                                                                                                              RIF+INH - 37 (90.3%)\                                                                                                                                                   Defaulted - 10\
                                                                                                                                                                                                                                                                                                                              RIF only - 5 (9.7%)                                                                                                                                                     Died - 13

  Dholakia and Shah, 2013\[[13](#fn13){ref-type="fn"}\]      Mumbai, Maharashtra                 August 2006-November 2010                                                                       29                                             Individualized                   3                                            Mono-resistant - 3 (11%)\                                                             Average - 7.8 (3-11) months                                                       Cured - 14 (51%)\
                                                                                                                                                                                                                                                                                                                              MDR-TB with EMB/PZA/EMB,\                                                                                                                                               Died - 5 (18%)\
                                                                                                                                                                                                                                                                                                                              PZA - 20 (69%) Pure MDR-TB - 4\                                                                                                                                         Failure - 2 (7%)\
                                                                                                                                                                                                                                                                                                                              XDR-TB - 1\                                                                                                                                                             Defaulted - 5 (18%)\
                                                                                                                                                                                                                                                                                                                              Resistance to at least one\                                                                                                                                             Migrated - 1\
                                                                                                                                                                                                                                                                                                                              SLD - 13 (44.8%)                                                                                                                                                        Still on treatment - 2

  Isaakidis *et al*., 2013\[[14](#fn14){ref-type="fn"}\]     Mumbai, Maharashtra                 July 2007-January 2013                                                                          11                                             Individualized + standardized    100                                          RIF+INH - 100%\                                                                                                                                                         Cured - 1\
                                                                                                                                                                                                                                                                                                                              EMB - 7/9 (78%)\                                                                                                                                                        Still on treatment - 3\
                                                                                                                                                                                                                                                                                                                              FQ - 6/8 (75%)\                                                                                                                                                         Died - 4 (36.5%)\
                                                                                                                                                                                                                                                                                                                              Injectable - 1/8 (13%)                                                                                                                                                  Defaulted - 3 (27%)

  Jain *et al*., 2014\[[15](#fn15){ref-type="fn"}\]          Ahmedabad, Gujarat                  January 2009-December 2009                                                                      130                                            Standardized                                                                  STM, RIF, INH, EMB - 61 (47%)\                                                        89 (68%) within 9 months\                                                         Cured - 51 (39%)\
                                                                                                                                                                                                                                                                                                                              STM, RIF, INH/RIF, INH,\                                                              3 months - 73 (82%)\                                                              Treatment completed - 7 (5%)\
                                                                                                                                                                                                                                                                                                                              EMB - 14 (10%)\                                                                       6 months - 84 (94%)                                                               Failure - 17 (13%)\
                                                                                                                                                                                                                                                                                                                              STM, RIF/RIF, INH - 49 (38%),\                                                                                                                                          Defaulted - 30 (23%)\
                                                                                                                                                                                                                                                                                                                              RIF - 6 (5%)                                                                                                                                                            Died - 25 (19%)

  Udwadia and Moharil, 2014\[[16](#fn16){ref-type="fn"}\]    Mumbai, Maharashtra                 May 2006-May 2010                                                                               78                                             Individualized                                                                RIF, INH - 100%\                                                                                                                                                        Cured - 53 (68%)\
                                                                                                                                                                                                                                                                                                                              STM - 74.4%\                                                                                                                                                            Failure - 12 (15%)\
                                                                                                                                                                                                                                                                                                                              EMB - 51.3%\                                                                                                                                                            Defaulted - 13 (16%)
                                                                                                                                                                                                                                                                                                                              PZA - 15.4%\                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                              OFX - 43.6%\                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                              PAS - 24.4%\                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                              KM - 17.9%\                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                              ETO - 32.1%                                                                                                                                                             

  Kapadia and Tripathi, 2014\[[17](#fn17){ref-type="fn"}\]   Ahmedabad, Gujarat                  August 2007-March 2010                                                                          66                                             Standardized                     1 (1.5)                                      STM, RIF, INH, EMB - 31 (63.3%)\                                                      Mean smear conversion - 4.2 2.2 months mean culture conversion - 4.3±2.5 months   Cured - 25 (37.87%)\
                                                                                                                                                                                                                                                                                                                              STM, RIF, INH- 9 (18.4%)\                                                                                                                                               Failure - 4 (6.1%)\
                                                                                                                                                                                                                                                                                                                              RIF, INH, EMB- 2 (4.3%)\                                                                                                                                                OFX - 2/XDR-TB - 2\
                                                                                                                                                                                                                                                                                                                              RIF, INH - 7 (14.3%)\                                                                                                                                                   Defaulted - 17 (25.75%)\
                                                                                                                                                                                                                                                                                                                              Line Probe Assay\                                                                                                                                                       Died - 17 (25.75%)\
                                                                                                                                                                                                                                                                                                                              RIF, INH- 13 (76.5%)\                                                                                                                                                   Treatment completed - 3 (4.54%)
                                                                                                                                                                                                                                                                                                                              RIF only - 4 (23.5%)                                                                                                                                                    

  Yadav *et al*., 2016\[[18](#fn18){ref-type="fn"}\]         Jaipur, Rajasthan                   2012                                                                                            115                                            Standardized                                                                  RIF, INH - 86 (74.8%)\                                                                3 months - 68 (59.1%)\                                                            Cure - 63.5%\
                                                                                                                                                                                                                                                                                                                              RIF alone - 29 (25.2%)                                                                6 months- 68.4%                                                                   Failure - 9.6%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Defaulted - 15.7%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Died - 11.3%

  Patel *et al*., 2016\[[19](#fn19){ref-type="fn"}\]         Vadodara, Gujarat (Western India)   March 2010-January 2013                                                                         145                                            Standardized                     2                                            STM, RIF, INH, EMB - 87 (60%)\                                                                                                                                          Cured- 48 (33.1%)\
                                                                                                                                                                                                                                                                                                                              STM, RIF, INH - 29 (20%)\                                                                                                                                               Treatment completed - 8 (5.5%)\
                                                                                                                                                                                                                                                                                                                              RIF, INH - 18 (12.4%)\                                                                                                                                                  Treatment failure - 9 (6.2%)\
                                                                                                                                                                                                                                                                                                                              STM, RIF - 2\                                                                                                                                                           Died - 43 (29.7%)\
                                                                                                                                                                                                                                                                                                                              RIF, INH, EMB - 6 (4.1%)\                                                                                                                                               Defaulted - 32 (21.1%)\
                                                                                                                                                                                                                                                                                                                              RIF, EMB - 1\                                                                                                                                                           Transferred - 3 (2.1%)\
                                                                                                                                                                                                                                                                                                                              RIF - 1                                                                                                                                                                 Switched to CAT V - 1\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Still on treatment (30 months) - 4 (2.8%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Compliancy to treatment- 81 (55.9%)

  Nair *et al*., 2016\[[20](#fn20){ref-type="fn"}\]          Tamil Nadu                          Conventional DST September 2010-September 2011 Rapid diagnostic September 2012-September 2013   Conventional DST - 135 Rapid diagnostic- 389   Standardized                     Only among rapid diagnostic group - 18 (5)   Conventional DST\                                                                     Conventional DST 6 months - 69 (51%)\                                             Conventional DST\
                                                                                                                                                                                                                                                                                                                              RIF, INH - 127 (94%)\                                                                 Rapid diagnostic 6 months - 208 (54%)                                             Cured - 31 (23%)\
                                                                                                                                                                                                                                                                                                                              RIF only - 7 (5%)\                                                                                                                                                      Treatment completed - 9 (7%)\
                                                                                                                                                                                                                                                                                                                              Rapid diagnostic\                                                                                                                                                       Died - 24 (18%)\
                                                                                                                                                                                                                                                                                                                              RIF, INH - 216 (56%)\                                                                                                                                                   Failure - 5 (4%)\
                                                                                                                                                                                                                                                                                                                              RIF only - 169 (43%)                                                                                                                                                    Loss to follow-up - 45 (33%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Transfer out - 2 (2%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Switched to XDR-TB treatment - 0 (0.0%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Stopped due to reasons other than ADR - 0 (0.0%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Missing data - 19 (13%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Rapid diagnostic\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Cured - 110 (28%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Treatment completed - 50 (13%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Died - 75 (20%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Failure - 1 (0.3%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Loss to follow-up - 120 (31%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Transfer out - 13 (3%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Switched to XDR-TB treatment - 7 (2%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Stopped due to reasons other than ADR - 1 (0.3%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Missing data - 12 (3%)

  Neeta *et al*., 2016\[[21](#fn21){ref-type="fn"}\]         Bellary, Karnataka                  December 2012-April 2013                                                                        43                                             Standardized                                                                  RIF, INH- 33 (76.7%)\                                                                 6 months - 20 (45.5%)\                                                            Cured- 9 (44.2%)\
                                                                                                                                                                                                                                                                                                                              RIF- 10 (23.3%)                                                                       12 months - 34.9%                                                                 Defaulted - 12 Died - 9\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Failure - 1 XDR-TB evaluation - 2

  Dole *et al*., 2017\[[22](#fn22){ref-type="fn"}\]          Solapur (Western Maharashtra)       September t 2012-December 2014                                                                  146                                            Standardized                     6                                                                                                                                  130 (89%) within 3 months                                                         Cured - 39 (27%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Treatment completed - 45 (31%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Died - 20 (14%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Defaulted - 28 (19%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Failure (Switch to CAT-V) - 14 (9%)

  Suryawanshi *et al*., 2017\[[23](#fn23){ref-type="fn"}\]   Maharashtra                         January 2011-December 2012                                                                      4024                                           Standardized                     138 (3.4)                                                                                                                                                                                                            Cured - 828 (20.6%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Treatment completed - 340 (8.4%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Died - 857 (21.3%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Lost to follow-up - 768 (19.1%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Failure - 98 (2.4%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Switched to CAT V treatment for XDR-TB - 190 (4.7%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Still on treatment - 239 (5.9%)

  Janmeja *et al*., 2017\[[24](#fn24){ref-type="fn"}\]       Chandigarh, Punjab                  January 2012-December 2014                                                                      140                                            Standardized                     4 (2.7)                                                                                                                            3 months - 98 (70%)\                                                              Cure - 77 (55%)\
                                                                                                                                                                                                                                                                                                                                                                                                                    6 months - 112 (81.4%)                                                            Treatment completed - 11 (7.8%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Died - 23 (16.4%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Defaulted - 13 (9.2%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Failure - 5 (3.5%) Switched to CAT V (XDR-TB) - 11 (7.8%)

  Waghmare *et al*., 2017\[[25](#fn25){ref-type="fn"}\]      Mumbai, Maharashtra                 August 2012 - December 2013                                                                     194                                            Standardized\                    8.8                                          MDR-TB - 59 (30.4%)\                                                                  Available for 133/194\                                                            Cured - 68\
                                                                                                                                                                                                                                                Individualized in cases of\                                                   MDR TB with additional FQ resistance (pre-XDR \[FQ\]) - 124 (64%)\                    3 months - 92 (69%)\                                                              Treatment completed - 26\
                                                                                                                                                                                                                                                Pre-XDR and XDR-TB                                                            MDR TB with additional AM resistance (preXDR \[AM\]) - 11 (5.6%) XDR TB - 10 (5.1%)   6-11 months- 125 (93.9%)                                                          Failure - 22 (11.3%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Died - 39 (20.15%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Defaulted - 23 (11.8%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Treatment completed with outcomes unknown - 26 (13.4%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Transferred out - 13 (6.7%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Treatment stopped due to ADRs - 3 (1.5%)

  Parmar *et al*., 2018\[[26](#fn26){ref-type="fn"}\]        7 states of India                   August 2007-March 2011                                                                          3712                                           Standardized                     58 (1.6)                                     RIF only - 187 (5.0%)\                                                                2735 (73.6%)\                                                                     Outcome defined for 2264/3712 (60.9%)\
                                                                                                                                                                                                                                                                                                                              RIF, INH only - 1058 (28.5%)\                                                         Median time- 100 days                                                             Cured - 781/2264 (34.5%)\
                                                                                                                                                                                                                                                                                                                              RIF, INH combination - 2407 (64.8%)\                                                                                                                                    Died - 644/2264 (28.4%)\
                                                                                                                                                                                                                                                                                                                              RIF combination - 50 (1.4%)\                                                                                                                                            Lost to follow up - 670/2264 (29.6%)\
                                                                                                                                                                                                                                                                                                                              Gujarat sub-group\                                                                                                                                                      Treatment failure or changed to XDR-TB treatment - 169/2264 (7.5%)\
                                                                                                                                                                                                                                                                                                                              OFX resistance - 62 (59.6%)\                                                                                                                                            Still on treatment - 1448/3712 (39%)
                                                                                                                                                                                                                                                                                                                              KM resistance - 8 (7.7%)\                                                                                                                                               
                                                                                                                                                                                                                                                                                                                              ETO resistance- 28 (26.9%)\                                                                                                                                             
                                                                                                                                                                                                                                                                                                                              XDR-TB - 6 (5.8%)                                                                                                                                                       

  Gupta and Jorwal, 2018\[[27](#fn27){ref-type="fn"}\]       New Delhi                           2009-2013                                                                                       819                                            Standardized                     18 (2.2)                                     RIF and INH- 100%\                                                                                                                                                      Cured - 415 (52%)\
                                                                                                                                                                                                                                                                                                                              EMB - 167 (58%)\                                                                                                                                                        Treatment completed - 23 (3%)\
                                                                                                                                                                                                                                                                                                                              STM - 222 (76.8%) OFX - 45 (78.9%)\                                                                                                                                     Default - 199 (24%)\
                                                                                                                                                                                                                                                                                                                              KM - 9 (69.2%)                                                                                                                                                          Died - 130 (16%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Switched to CAT V - 27 (3%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Transferred out - 12 (1%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Treatment failure - 13 (1%)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MDR-TB: Multidrug-resistant tuberculosis, RIF: Rifampin, INH: Isoniazid, EMB: Ethambutol, PZA: Pyrazinamide, STM: Streptomycin, CS: Cycloserine, ETO: Ethionamide, OFX: Ofloxacin, XDR: Extensively drug-resistant, CAT V: Category V, DST: Drug sensitivity testing, ADR: Adverse drug reaction, FQ: Fluoroquinolone, AM: Amikacin, KM: Kanamycin
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In our study, the culture conversion rate was 87.7%, which was in accordance with previous studies reporting conversion rates ranging from 74% to 92%,\[[@ref5][@ref6][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25][@ref26]\] suggesting that adoption of the modified DOTS-Plus strategy might be a cost-effective strategy, particularly in high MDR-burden resource-limited setting like India. Reduction in culture examinations in the continuation phase can also help in diversion of available resources in further expansion of the existing program to cater to unmet populations.

Certain characteristics were responsible for poor treatment outcome in this study such as drug addiction, previous history of TB episodes \>2, and resistance to KM as well as OFX, as reported in other studies.\[[@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25][@ref26][@ref27]\] Many studies with diversity in demographic profile, setting, and methodology have reported other characteristics such as alcoholism, diabetes, extensive cavitary lesions, and HIV seropositivity with poor outcome, although not observed in our study due to limited sample size and no HIV seropositivity in our cohort.

Overall, 119 AEs were reported in 46 (46.9%) patients. The most commonly grouped AEs were gastrointestinal followed by ototoxicity and arthralgia as reported similarly in other studies.\[[@ref28][@ref29][@ref30][@ref31][@ref32][@ref33]\] Major AEs were reported in 17.4% of patients, which is lower in comparison to other studies.\[[@ref28][@ref29][@ref30][@ref31][@ref32][@ref33]\] Among major AEs, the most common was deafness induced by KM and psychosis by CS. This lower incidence may be attributed to the adopted methodology for active surveillance and systematic periodic follow-up.

A major issue of concern still remains that 21/132 (15.9%) patients were excluded from our study as 8 (6.1%) were exposed to SLDs \>1 month and 13 (9.8%) showed non-MDR resistance patterns. These subset of patients could lead to amplification of drug resistance in households and community if left untreated. There could also be a high probability of either suboptimal treatment outcome with standardized regimen or baseline resistance to SLDs at initiation of treatment responsible for failure detected during the course of treatment. Appropriate individualized regimens based on DST pattern would be preferred for treating these subset of patients. Several studies from urban sector reported remarkable treatment success rate with individualized regimens ranging from 48.4% to 68%.\[[@ref15][@ref22][@ref23][@ref25][@ref26][@ref27]\] A systematic review and meta-analysis reported that individualized regimens had better outcome (successful rate -- 67.2%; unsuccessful rate -- 30.8%) than standardized regimens (successful rate -- 56.9%; unsuccessful rate -- 43%) as prescribed under the DOTS-Plus programs.\[[@ref15]\] However, treatment with individualized regimens remains challenging in resource-limited settings requiring support of quality-assured laboratory facilities and expertise in interpretation of results with prescription of appropriate regimens.

There is expanding evidence over the last decade regarding the management of MDR-TB patients under national PMDT program. Additional SLD\'s resistance even at baseline, created by irrational use of drugs especially in private sector, has significantly increased and has become a major issue.\[[@ref17][@ref25][@ref26][@ref27]\] Majority of TB patients seek consultation from private sector, but the quality of care remains suboptimal with undernotification of cases, wide variations in knowledge, poor adherence to guidelines, and misuse of SLDs leading to increase in drug resistance.\[[@ref34][@ref35][@ref36][@ref37]\] The introduction of genotypic diagnostic tests (GeneXpert, line probe assays) providing rapid diagnosis and individualized regimens fortified with newer drugs (bedaquiline and delamanid) has created revolution in the management of DR-TB patients. The recently released national PMDT guidelines focus on the active surveillance of disease and AE, re-classification of drugs, individualized regimens according to the most recent pattern of DST, patient-centric approach, universal DST, and engagement of private sector.\[[@ref38]\]

Current national guidelines primarily rely on culture reports for treatment regimen optimization, i.e., shift from IP to continuation phase (CP) and decision to define the outcome of treatment. Monitoring with follow-up cultures entails time, travel, and work loss costs for the patient and because culture result by the conventional method is not available before a lag period of approximately 6--8 weeks, there is a delay in decision-making by health-care professionals.\[[@ref5]\] It is observed that culture conversion which reflects the viability of tubercle bacilli is more sensitive and is considered necessary to monitor progress in MDR-TB patients. There was no significant difference between smear conversion rate and culture conversion rate at 4 months (69.2% vs. 67.1%; 95% CI:-11.3 − 15.4; *P* = 0.76), 6 months (88.9% vs. 83.3%; 95% CI:-4.7 − 15.9; *P* = 0.28), and 12 months (93.1% vs. 89.7%; 95% CI:-5.4 − 12.4; *P* = 0.43). The trend of diagnostic accuracy of smear examination with reference to culture as gold standard during the course of treatment is described in [online Supplementary Table S4](#T10){ref-type="table"}. This supports findings from a previous study showing the potential role of the smear conversion rate as a surrogate of culture conversion, especially in resource-limited high-burden countries like India as early decision regarding transition from IP to CP can be made resulting in reduction in cost of drugs to health system as well as patients, duration of hospitalization, and AEs related to drugs.\[[@ref39]\] However, findings of smear examination need to be interpreted cautiously as it has less sensitivity than culture and does not differentiate between live and dead bacilli or other species such as atypical mycobacterial species leading to false positives. Reducing follow-up cultures might delay the confirmation of bacteriological conversion and could delay the diagnosis of possible treatment failure before conversion.\[[@ref40]\] Therefore, these findings need to be confirmed with more studies involving larger number of samples. Our study has adopted modified DOTS strategy and reported satisfactory treatment outcome of MDR-TB patients at that point of time when the national DOTS-Plus program was in expansion phase and genotypic tests were to be included for diagnosis. However, the study was hospital based involving small number of patients. Further community-based studies are required to validate these findings.

###### 

Diagnostic accuracy of smear with culture as reference during the course of multidrug-resistant tuberculosis treatment

  Duration of treatment (months)   Smear + Culture +   Smear + Culture −   Smear − Culture +   Smear − Culture −   Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)
  -------------------------------- ------------------- ------------------- ------------------- ------------------- ----------------- ----------------- --------- ---------
  0                                98                  0                   0                   0                   98                0                 98        0
  4                                15                  13                  15                  48                  50.0              78.7              53.6      76.2
  6                                10                  0                   5                   75                  66.7              100               100       93.8
  12                               6                   0                   4                   77                  60                100               100       95.1
  18                               7                   0                   2                   75                  77.8              100               100       97.4
  24                               7                   0                   0                   75                  100               100               100       100

Six patients were smear +/culture+at 12 months of treatment. The PPV of smear was high at start as most smear+are culture +, but with treatment, it decreased as chance of dead bacilli increased and smear+could be culture −. However, at 6 months, PPV again approached 100%, leading to satisfactory corroboration between sputum and culture positivity as majority of the dead bacilli were excreted. The NPV of smear was high after 4 months of treatment as smear−reflects culture in most situations. The NPV approached to 93% or more from 6 months onwards. The specificity of smear test gradually increased during treatment and from 6 months onward the specificity was 100%, indicating that after the 6^th^ month, the probability of false positivity with smear would be less. The sensitivity of smear was variable with higher values at the beginning and near the end of treatment with variability in between, indicating that the false negatives were low during this period. PPV: Positive predictive value, NPV: Negative predictive value

CONCLUSION {#sec1-5}
==========

There is no doubt that the current PMDT program has expanded its services throughout the nation and is rigorously providing every effort to manage more and more DR-TB cases effectively by scaling up laboratory facilities with genotypic tests and appropriate regimens including newer drugs. Despite this effort, an enormous burden of DR-TB cases in high-burden countries like India, especially in private sector, still remains uncovered. This can be considered to be a great hurdle in achieving the ambitious goal of elimination of TB by 2025.\[[@ref41]\] The modified DOTS-Plus strategy adopted in our study can support national programs in the reduction of burden of DR-TB cases in resource-limited settings, especially in private sector. It should be made flexible as well as less stringent according to local needs but should be kept aligned to the existing national PMDT guidelines. A systematic approach is required for curbing down the epidemic of DR-TB cases by implementing cost-effective and sustainable interventions in the near future.
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